TopFunds

Dexcom

NASDAQ: DXCM

Stock price

76.65 USD

(+Infinity%) NaN day

Health Care EquipmentMedical - Devices

Financial Performance

Share

5Y price score: (43)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 295.3%

DATE RANGE:

US$ Per
Share

    Time scale:

    By default your notes are visible only to you.

    54.1

    52-week range

    89.9

    76.65

    Your model inputs

    Required return / cost of capital
    %
    FCFF terminal growth rate
    %

    Your fair value & Margin of safety

    To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

    Forecast:

    Valuation

    Free Cash Flow Yield

    Help
    FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

    4.6 %

    Dividend Yield TTM

    -

    Market cap $

    $ 29,577

    Price / Earnings TTM

    Help
    P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

    32.8

    Price / Book TTM

    10

    PEG TTM

    Help
    Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

    0.7

    Earnings growth and return

    LTM

    5YR

    10YR

    Total return (price & dividends)

    (8.9) %

    (31.7) %

    295.3 %

    Free cash flow per share growth

    73.8 %

    274.6 %

    5,300.9 %

    Earnings per share growth

    47.2 %

    64.6 %

    1,261.1 %

    Founded: 1,999

    Employees: 10,200

    Business Summary:DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

    Fair Value Reference Estimate

    Latest Earnings Call Takeaways

    Annual Reports, Presentations And IR Contacts

    Go to the website
    Annual report links (10K)
    2025202420232022202120202019201820172016

    Dexcom — Financial Overview, Stock Price, Market Cap

    Dexcom is a company. Founded in 1999. As of July 20, 2026, the company's market capitalization is $29577163687 with a current stock price of $76.65.